Although RYH is lighter on blue chip pharma names compared to its cap-weighted counterparts, the ETF does not short change investors when it comes to high-quality firms. The ETF is home to several companies with decades-long dividend increase streaks such as Johnson & Johnson (NYSE: JNJ) and Abbott Labs (NYSE: ABT).

Additionally, a substantial percentage of RYH’s holdings have been rumored to be takeover targets, a trait found with more than a few health care ETFs these days. Nearly a third of RYH’s 55 holdings have at some point been rumored to be takeover targets, are in the process of being acquire or, in the case o Allergan (NYSE: AGN), warding off a hostile takeover.

Investors like RYH’s story. When we last highlighted the ETF less than two months ago, it had $321.6 million in assets under management. That number is now above $360 million.

Guggenheim S&P Equal Weight Healthcare ETF